FUSILEV Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Fusilev, and what generic alternatives are available?
Fusilev is a drug marketed by Acrotech Biopharma and is included in one NDA.
The generic ingredient in FUSILEV is levoleucovorin calcium. There is one drug master file entry for this compound. Seven suppliers are listed for this compound. Additional details are available on the levoleucovorin calcium profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Fusilev
A generic version of FUSILEV was approved as levoleucovorin calcium by SANDOZ on March 9th, 2015.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for FUSILEV?
- What are the global sales for FUSILEV?
- What is Average Wholesale Price for FUSILEV?
Summary for FUSILEV
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 63 |
Clinical Trials: | 5 |
Patent Applications: | 5,445 |
Drug Prices: | Drug price information for FUSILEV |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for FUSILEV |
What excipients (inactive ingredients) are in FUSILEV? | FUSILEV excipients list |
DailyMed Link: | FUSILEV at DailyMed |
Recent Clinical Trials for FUSILEV
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Academic and Community Cancer Research United | Phase 1/Phase 2 |
National Cancer Institute (NCI) | Phase 1/Phase 2 |
Amgen | Phase 3 |
Paragraph IV (Patent) Challenges for FUSILEV
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
FUSILEV | Injection | levoleucovorin calcium | 50 mg/vial | 020140 | 1 | 2013-12-19 |
FUSILEV | Injection | levoleucovorin calcium | 10 mg/mL, 17.5 mL vial and 25 mL vial | 020140 | 1 | 2011-10-26 |
US Patents and Regulatory Information for FUSILEV
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Acrotech Biopharma | FUSILEV | levoleucovorin calcium | POWDER;INTRAVENOUS | 020140-001 | Mar 7, 2008 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Acrotech Biopharma | FUSILEV | levoleucovorin calcium | SOLUTION;INTRAVENOUS | 020140-002 | Apr 29, 2011 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Acrotech Biopharma | FUSILEV | levoleucovorin calcium | SOLUTION;INTRAVENOUS | 020140-003 | Apr 29, 2011 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for FUSILEV
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Acrotech Biopharma | FUSILEV | levoleucovorin calcium | POWDER;INTRAVENOUS | 020140-001 | Mar 7, 2008 | ⤷ Sign Up | ⤷ Sign Up |
Acrotech Biopharma | FUSILEV | levoleucovorin calcium | SOLUTION;INTRAVENOUS | 020140-003 | Apr 29, 2011 | ⤷ Sign Up | ⤷ Sign Up |
Acrotech Biopharma | FUSILEV | levoleucovorin calcium | SOLUTION;INTRAVENOUS | 020140-002 | Apr 29, 2011 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for FUSILEV
See the table below for patents covering FUSILEV around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Germany | 3752384 | ⤷ Sign Up | |
South Africa | 8706562 | ⤷ Sign Up | |
Japan | S63115880 | OPTICALLY ACTIVE COMPOUND | ⤷ Sign Up |
European Patent Office | 1275393 | Composition pharmaceutique contenant un dérivé de ptéridine (Pharmaceutical formulation containing pteridine derivative) | ⤷ Sign Up |
Australia | 598024 | ⤷ Sign Up | |
>Country | >Patent Number | >Title | >Estimated Expiration |